Description
Femara is an anti-estrogen of the Aromatase Inhibitor (AI) family and is one of the most potent and powerfully effective of all AI’s. In fact, its potency is sometimes too much for some to handle when used for off label use. Letrozole first gained U.S. FDA approval in 1997 and would hit the market under the brand name Femara through Novartis. Although Femara is the dominating trade name of the AI, unlike most AI’s it is the only one generally known by its chemical name Letrozole far more commonly than its dominating brand name.
Femara was first developed in an effort to combat breast cancer in post-menopausal women. In fact, it would prove to be virtually identical to the already popular AI in Arimidex (Anastrozole). While intended for breast cancer treatment, like many AI’s, it has found a welcomed home among anabolic steroid users. Letrozole is one of the most commonly used anti-estrogens among steroid users during steroid use to combat possible estrogenic related side effects. It is so effective as an anti-estrogen in this regard many anabolic steroids have effectively reversed gynecomastia symptoms with Letrozole.
